Pfizer's Umpteenth Settlement (for $491 Million Plus a Guilty Plea), but No Person Held Responsible
The world's largest research based pharmaceutical company was in court again, as reported by the New York Times, The drug maker Pfizer agreed to pay $491 million to settle criminal and civil charges over the illegal marketing of the kidney-transplant drug Rapamune, the Justice Department announced on Tuesday. In particular, The recent case centers on the practices of Wyeth Pharmaceuticals, which Pfizer acquired in 2009.Rapamune, which prevents the body’s immune system from rejecting a transplanted organ, was approved by the Food and Drug Administration in 1999 for use in patients receiving a kidney transplant. However, federal officials said Wyeth aggressively promoted the drug for use in patients receiving other organ transplants, even offering financial incentives to its sales force to do so. Accusations of Wyeth’s practices became public in 2010 after a whistle-blower lawsuit filed by two former employees was unsealed. After lawmakers announced a Congressional inquiry, the Justice Department opted to join the lawsuit. The settlement announced Tuesday, which also resolves a second, similar whistle-blower suit, includes a criminal fine and forfeiture of $233.5 million, and a civil settlement of $257.4 million with the federal government, all 50 states and the District of Columbia. The case did not get much media coverage. So far, the only other somewhat detailed article on it was put out by Bloomberg. In fact, the lawyer fo...
Publication date: Available online 30 May 2020Source: Annals of Medicine and SurgeryAuthor(s): Abu Bakar H. Bhatti, Roshni Z. Jafri, Nasir A. Khan
Publication date: Available online 30 May 2020Source: African Journal of Emergency MedicineAuthor(s): Farahnaz Farahbakhsh, Mehdi Torabi, Moghaddameh Mirzaee
CONCLUSION: Neurotoxicity is an underrated reversible side effect of chronic tacrolimus administration after organs' transplantation. Its prompt diagnosis, based on T2 and FLAIR MRI sequences neuroimaging combined with stereotactic biopsy, allows the discontinuation of the drug and a recovery of the patient in most of the cases. KEY WORDS: Stereotactic Biopsy, Neurotoxicity, Tacrolimus, Transplant Complications, Transplantation, Tumorlike Lesion. PMID: 32469336 [PubMed - as supplied by publisher]
Authors: Poznyak AV, Zhang D, Grechko AV, Wu WK, Orekhov AN Abstract Atherosclerosis is a major cause of disease-related mortality around the globe. The main characteristic of the disease is an accumulation of plaque on the arterial wall and subsequent erosion or rupture of some plaques. Atherosclerosis often leads to cardiovascular disease and such acute complications as myocardial infarction or ischaemic stroke due to thrombus formation. Most recent advances in atherosclerotic research state that the modifications of low- density lipoprotein (LDL) are one of the most significant stages in the disease initiation, ...
Publication date: Available online 30 May 2020Source: Neuroscience LettersAuthor(s): Halil Ibrahim Çikriklar, Dilcan Kotan, Murat Yücel, Mustafa Ceylan, Gönül G. Çiftçi, Ömer F. Bayraktutan, Ihsan H. Çiftçi
This article reports on maxillary canine autotransplantations combined with connective tissue grafts (CTGs) and orthodontics. The recipient mesiodistal space was created orthodontically and the recipient socket was prepared using dental implant drills. Following transplantation, bone defects were grafted using guided bone regeneration (GBR). At 4 years post-transplantation, the soft tissue level was stable and periapical radiographs showed a practically normal contour of the alveolar crest around teeth 13 and 23. The two permanent canines presented no root resorption and ankylosis, and no signs of inflammation or bleeding ...
Conclusions: Interleukin-6 may be an indicator of inflammatory activity in psoriasis. Moreover, IL-6 may be related to lipid abnormalities in patients with this disease. PMID: 32467682 [PubMed]
CONCLUSION: Current literature suggests an important and growing concern for the abuse of PRG. Male sex, psychiatric and/or addiction history, including opioid addiction, may be potential risk factors for the development of addictive behaviours associated with PRG. PMID: 32471706 [PubMed - as supplied by publisher]
Authors: Anagnostis P, Vaitsi K, Mintziori G, Goulis DG, Mikhailidis DP PMID: 32468870 [PubMed - as supplied by publisher]
Authors: Paraskevas KI, Liapis CD, Veith FJ PMID: 32468867 [PubMed - as supplied by publisher]
More News: Appendicitis | Asbestosis | Atorvastatin Calcium | Cancer & Oncology | Cholesterol | Detrol | Epilepsy | Food and Drug Administration (FDA) | Gabapentin | Government | Health | Health Management | Health Medicine & Bioethics Commentators | Hormones | Kidney Transplant | Kidney Transplantation | Lawsuits | Legislation | Linezolid | Lipitor | Liver | Liver Transplant | Lung Transplant | Lyrica | Marketing | Medicaid | Medical Law | Medicare | Neurology | Neurontin | Pantoprazole | Pfizer | Politics | Proton Pump Inhibitors PPIs | Protonix | Statin Therapy | Transplant Surgery | Transplants | Urology & Nephrology | Zivast | Zyvox